NYSEAMERICAN : SER

Serina Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.94 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 49.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Details

NameSerina Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees16
Founded2017
Ipo Date2018-11-29
CeoSteven Ledger
CountryUnited States
ExchangeNYSEAMERICAN
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS81751A1088
Cusip81751A108
Cik0001708599
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Steven A. LedgerChief Executive Officer and Director
Dr. Balkrishan Gill Ph.D.Executive Co-Chairman of the Board
Dr. J. Milton Harris Ph.D.Co-Founder, Director Emeritus and Chair of Scientific Advisory Board
Dr. Srini Tenjarla Ph.D.Chief Technical Operations Officer
Dr. Randall W. Moreadith M.D., Ph.D.Chief Development Officer
Gregory S. CurhanChief Financial Officer
Dr. Joshua Thomas Ph.D.Head of Chemistry

Contact

Address601 Genome Way, Suite 2001, Huntsville, Alabama 35806, United States
Phone256 327 9630
Websitehttps://www.serinatx.com